News Briefs: FDA OKs First Generic of Daily GLP-1 Injection
-
Dec 24, 2024
The FDA on Dec. 23 approved the first generic GLP-1 once-daily injectable for patients with Type 2 diabetes. The generic for Victoza (liraglutide) is particularly important because Victoza is in shortage, noted the FDA, which also approved the first generic version of twice-daily GLP-1 Byetta (exenatide) last month. Liraglutide reduces blood sugar in patients ages 10 and older with Type 2 diabetes. On Dec. 20, the FDA also approved a new indication for another GLP-1, Zepbound (tirzepatide), for the treatment of obstructive sleep apnea in adults with obesity.
Johnson & Johnson sued The Cigna Group’s Express Scripts PBM and Accredo specialty pharmacy, accusing them of profiting from J&J’s copay assistance funds, the Wall Street Journal reported. J&J added the Cigna divisions to its original lawsuit against middleman SaveOnSP LLC, accusing all three of working together to drain J&J of $100 million more in assistance funds. According to the suit, SaveOn increased the copay amount on certain drugs, billed J&J’s copay assistance program, and pushed payments to SaveOn’s drug benefit plan, paying itself a commission. The amended lawsuit accuses Express Scripts and Accredo of working with SaveOn in this arrangement. J&J is seeking damages to be specified in court.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.